Table 2.
P0 |
P2 |
||||
---|---|---|---|---|---|
Pre | Post | Pre | Post | ||
MHC (%) | MHC-I | 63 ± 5 | 57 ± 5* | 63 ± 5 | 65 ± 4 |
MHC-IIA | 32 ± 4 | 38 ± 5* | 30 ± 4 | 31 ± 4 | |
MHC-IIX | 6 ± 2 | 5 ± 5 | 7 ± 2 | 4 ± 1* | |
Number (%) | Type 1 | 56 ± 6 | 51 ± 5 | 52 ± 4 | 60 ± 3 |
Type 2a | 29 ± 3 | 34 ± 4* | 30 ± 4 | 29 ± 3 | |
Type 2b | 15 ± 4 | 15 ± 2 | 18 ± 3 | 11 ± 1* | |
Area (%) | Type 1 | 62 ± 6 | 56 ± 6* | 58 ± 5 | 65 ± 4 |
Type 2a | 28 ± 4 | 34 ± 5* | 28 ± 4 | 27 ± 4 | |
Type 2b | 10 ± 2 | 11 ± 2 | 14 ± 4 | 8 ± 1* |
Data are presented as mean values ± s.e.m. for P0 (n = 7) and P2 (n = 6) before (Pre) and after (Post) a 12 week training period.
Significantly different from Pre (P < 0.05).